Key FDA approval (April 2026) FDA approved orforglipron (Foundayo) - first oral non-peptide GLP-1 receptor agonist Indication: chronic weight management in adults with obesity OR overweight + 1 comorbidity Must be combined with lifestyle intervention (diet +physical activity) #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @CMichaelGibson @SubodhVermaMD @DrMarthaGulati @hvanspall @ShelleyZieroth @ankeetbhatt @vuralmg @cardioceptor @Hragy Key FDA approval (April 2026) FDA approved orforglipron (Foundayo) - first oral non-peptide GLP-1 receptor agonist Indication: chronic weight management in adults with obesity OR overweight + 1 comorbidity Must be combined with lifestyle intervention (diet +physical activity) #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @CMichaelGibson @SubodhVermaMD @DrMarthaGulati @hvanspall @ShelleyZieroth @ankeetbhatt @vuralmg @cardioceptor @Hragy
Comprehensive Treatment: Typically prescribed as part of a comprehensive weight loss program, including lifestyle modifications and dietary changes
However, both agencies concluded that the currently available evidence does not support a causal relationship between GLP-1 drugs and suicidal thoughts or actions (9,10)
The net effect likely depends on individual patient factors and how well the pro-thrombotic risks are managed
Many people see improvements in blood pressure, cholesterol levels, inflammation markers, and cardiovascular risk factors
The most common side effects are gastrointestinal, including nausea (affecting 2040% initially), vomiting, diarrhoea, and constipation
